Purdue Research Foundation

University of Kansas

University of Michigan

Wayne State University

Sanford-burnham Medical Research Institute

Yale University

University of Rochester

Southern Research Institute

Daniel Patrick Flaherty

Val J Watts

Richard M Van Rijn

Jennifer Elizabeth Golden

Jeffrey Aube

Jatinder Kaur

Anthony B Pinkerton

Randal J Kaufman

Michael P Hedrick

Thomas D Y Chung

Andrew M Fribley

Jason A Scott

Mohamed Seleem

Paul M Dunman

Denise S Simpson

Damian J Krysan

Lynn Rasmussen

Joseph N Contessa

Daljit S Matharu

William E Severson

Xufeng Cao

Rasmussen Lynn

The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.

Pyrazolyl pyrimidinone compounds and the uses thereof

The invention described herein generally relates to novel therapeutic compounds, and in particular to carbonic anhydrase inhibitors as a narrow spectrum antibiotics against drug resistant bacteria and methods for treating those infection diseases in mammals using the described carbonic anhydrase inhibitors or a pharmaceutical formulation thereof.

Carbonic anhydrase inhibitors and antibiotics against multidrug resistant bacteria

Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence

The present invention includes novel compounds and methods for preventing or treating diseases associated with N-linked glycosylation in a subject in need thereof. The methods comprise administering to the subject an effective amount of at least one compound of the invention.

Inhibitors of-linked glycosylation and methods using same

N-substituted sulfonylphenyl-5-nitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the Unfolded Protein Response are provides as is their use in the treatment of diseases such as diabetes, Alzheimer's, Parkinson's, hemophilia, lysosomal storage diseases and cancer.

Compounds and methods for activating the apoptotic arm of the unfolded protein response

This present application disclosed a series of selective adenylyl cyclase 1 (AC1) inhibitors, compounds having a formula or a pharmaceutically acceptable salt thereof, as a pain therapeutic. Those compounds may provide an effective method of treatment for chronic/inflammatory pain. Those compounds may also prevent opioid dependence and/or reduce opioid dependence. Both method and composition matters are within the scope of this invention.

Adenylyl cyclase inhibitors for chronic pain and opioid dependence

Provided herein are compositions and methods for treating or preventing infection.

Methods and compositions for treating infection

N-substituted sulfonylphenyl-5-mitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the Unfolded Protein Response are provided as is their use in the treatment of diseases such as diabetes, Alzheimer's, Parkinson's, hemophilia, lysosomal storage diseases and cancer.

Described herein are compounds, pharmaceutical compositions and methods for treating a respiratory syncytial virus infection in a subject, or for inhibiting replication of respiratory syncytial virus.

Inhibitors of respiratory syncytial virus

Growing community of inventors

West Lafayette, IN, United States of America

Daniel Patrick Flaherty